HCW Biologics Inc. (HCWB)
| Market Cap | 6.30M -51.4% |
| Revenue (ttm) | 6.72M +707.0% |
| Net Income | -21.41M |
| EPS | -27.18 |
| Shares Out | 1.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 127,493 |
| Open | 3.200 |
| Previous Close | 3.170 |
| Day's Range | 3.000 - 3.430 |
| 52-Week Range | 1.500 - 38.160 |
| Beta | 2.36 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About HCWB
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a... [Read more]
Financial Performance
In 2025, HCW Biologics's revenue was $54,232, a decrease of -97.89% compared to the previous year's $2.57 million. Losses were -$22.30 million, -25.73% less than in 2024.
Financial StatementsNews
HCW Biologics Registration statement: Registration filing
HCW Biologics filed a registration statement on August 28, 2026, providing details about a securities offering with the SEC.
HCW Biologics' TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
Human studies show that the TGF-β trap and IL-15 fusion used alone promotes expansion of progenitor CD8 + T cells and NK cells Company has incorporated the TGF-β/IL-15 moiety into the constructs of it...
HCW Biologics files to sell 1.24M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.24M shares of common stock. The company is not selling any…
HCW Biologics Registration statement: Registration filing
HCW Biologics filed a registration statement on August 20, 2026, providing details about a securities offering with the SEC.
HCW Biologics Earnings release: Q2 2026
HCW Biologics released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
HCW Biologics Quarterly report: Q2 2026
HCW Biologics has published its Q2 2026 quarterly earnings report on August 14, 2026.
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
MIRAMAR, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative f...
HCW Biologics announces pricing of $1.6M private placement
HCW Biologics (HCWB) announced the pricing of its $1.6M private placement offering with a group of investors, including officers, directors and an existing stockholder of the company. Pursuant to a…
HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
MIRAMAR, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immu...
HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027
Company requested Type B pre-IND meeting with U.S. FDA to discuss development and regulatory strategy for its investigational tetravalent T-cell engager, HCW11-018b HCW11-018b has demonstrated potenti...
HCW Biologics regains compliance with Nasdaq
HCW Biologics (HCWB) reported that the Nasdaq Hearings Panel of Nasdaq found that the company regained compliance with Listing Rule 5550, the “Bid Price Rule,” per the terms set forth…
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
MIRAMAR, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative f...
Hcw Biologics Inc trading halted, news pending
19:50 EDT Hcw Biologics (HCWB) Inc trading halted, news pending
HCW Biologics announces 1-for-6 reverse stock split
HCW Biologics (HCWB) announced that its board has approved a 1-for-6 reverse stock split of the company’s common stock, par value $0.0001, which will be effective at 12:01 a.m. Eastern…
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
Company completed 28 consecutive trading days above $1.00 per share on June 25, 2026 Reverse stock split effectuated to ensure ongoing compliance with the Bid Price Rule and additional requirements fr...
HCW Biologics Registration statement: Registration filing
HCW Biologics filed a registration statement on June 18, 2026, providing details about a securities offering with the SEC.
HCW Biologics announces data from first two dose cohorts of HCW9302 trial
HCW Biologics (HCWB) announced a preliminary human data readout for the first two dose cohorts from its dose-escalating Phase 1 clinical trial of HCW9302, an IL-2 based fusion immunotherapeutic, in…
HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata
Potentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T cells Readout for dose-escalating clinical study for first two dose cohorts All particip...
HCW Biologics Transcript: AGM 2026
Key milestones included $17.5M equity raised, debt repayment, and clinical trial progress. Five shareholder proposals were approved, including director elections, auditor ratification, and warrant-related actions. Strategic focus remains on advancing clinical programs and business development.
HCW Biologics registers to sell 5.69M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholder of up to 5.69M shares of common stock. The company is not selling any…
HCW Biologics Registration statement: Registration filing
HCW Biologics filed a registration statement on June 8, 2026, providing details about a securities offering with the SEC.
HCW Biologics price target raised to $5 from $2 at Maxim
Maxim raised the firm’s price target on HCW Biologics (HCWB) to $5 from $2 and keeps a Buy rating on the shares. The company has taken several steps to improve…
HCW Biologics CEO buys $160K in common stock
In a regulatory filing, HCW Biologics (HCWB) disclosed at its CEO Hing bought 113,879 shares of common stock on May 22nd in a total transaction size of $160K. Shares are…
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market Recently published data suggest that HCW9206 may reduce CAR-T production costs and improve therape...
E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the sol...